Findings showed both zanidatamab treatment arms demonstrated statistically significant and clinically meaningful improvements in PFS vs the SOC arm.

Ziihera® plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab ...

Clinical features, genomic alterations, and survival outcomes for variant histology urothelial carcinoma. Real-world (rw) treatment (tx) patterns and clinical outcomes in patients (pts) with locally ...

Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial While the ...

BioAtla, Inc. has announced promising preliminary results from a Phase 1 clinical trial of BA3182, a dual-Conditionally Active Biologic bispecific T-cell engager targeting EpCAM and CD3, for treating ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Samuel J. Klempner ...